Arbutus Biopharma Corp Total Contract Liability
Arbutus Biopharma Corp (ABUS) had Total Contract Liability of $0 as of 2025-06-30, per its 10-Q filed 2025-08-06.
Financial Statements › Balance Sheet › Liabilities
us-gaap:ContractWithCustomerLiability · last filed 2025-08-06
- 2025-06-30: Contract with Customer, Liability $0.00.
- 2025-03-31: Contract with Customer, Liability $9.62M.
- 2024-12-31: Contract with Customer, Liability $10.43M.
- 2024-09-30: Contract with Customer, Liability $10.91M.
| Period end | Contract with Customer, Liability |
|---|---|
| 2025-06-30 | $0.00 10-Q · filed 2025-08-06 |
| 2025-03-31 | $9.62M 10-Q · filed 2025-05-14 |
| 2024-12-31 | $10.43M 10-K · filed 2025-03-27 |
| 2024-09-30 | $10.91M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $11.03M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $11.55M 10-Q · filed 2024-05-02 |
| 2023-12-31 | $11.79M 10-K · filed 2024-03-05 |
| 2023-09-30 | $12.11M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $15.33M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $18.35M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $22.45M 10-K · filed 2023-03-02 |
| 2022-09-30 | $25.46M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $27.82M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $38.84M 10-Q · filed 2022-05-05 |
| 2018-12-31 | $0.00 10-K · filed 2019-03-07 |
| 2018-09-30 | $649.00K 10-Q · filed 2018-11-07 |
| 2018-06-30 | $974.00K 10-Q · filed 2018-08-03 |
| 2017-12-31 | $2.74M 10-K · filed 2019-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |